Quantcast
Last updated on April 21, 2014 at 1:20 EDT

Latest Kallikrein Stories

2012-11-05 04:21:53

SOUTHAMPTON, England, November 5, 2012 /PRNewswire/ -- KalVista Pharmaceuticals ("KalVista") today announces it has won a GBP2.4 million grant from the Technology Strategy Board under the UK Government's GBP180 million Biomedical Catalyst funding initiative for research and development in the life sciences. KalVista will use the new funding to accelerate the development of an oral plasma kallikrein inhibitor for the treatment of diabetic macular edema (DME), the leading cause of...

2011-08-23 03:00:00

SOUTHAMPTON, England, August 23, 2011 /PRNewswire/ -- KalVista Pharmaceuticals ("KalVista"), a new ophthalmology company with a focus on diabetic macular edema (DME), has raised GBP8 million in a series A round from leading life sciences investors Novo A/S and SV Life Sciences. The Company is developing novel, small molecule plasma kallikrein inhibitors, which represent a new approach to the treatment of DME, a leading cause of adult visual loss in developed countries and...

2011-02-10 06:00:00

SEATTLE, Feb. 10, 2011 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER) today announced that research on the antifibrinolytic agents it is developing has been published in the February 11, 2011 issue of the Journal of Biological Chemistry and selected by the editors as one of the top one percent of papers reviewed by the Journal in terms of significance and overall importance. This work from the laboratory of S. Paul Bajaj, Ph.D., demonstrates that unique antifibrinolytic agents can be...

2011-01-05 06:00:00

SEATTLE, Jan. 5, 2011 /PRNewswire/ -- Omeros Corporation (Nasdaq: OMER) today announced that it has obtained an exclusive license from The Regents of the University of California to a new series of antifibrinolytic agents. These optimized agents represent a significant potential advance in the control of surgical and traumatic bleeding. "This is a good opportunity for Omeros and represents a potential life-saving treatment for patients. With the withdrawal of Trasylol®...

2009-10-29 15:56:36

A harmless digestive enzyme evolved twice into a dangerous toxin in 2 unrelated species Biologists have shown that independent but similar molecular changes turned a harmless digestive enzyme into a toxin in two unrelated species -- a shrew and a lizard -- giving each a venomous bite. The work, described this week in the journal Current Biology by researchers at Harvard University, suggests that protein adaptation may be a highly predictable process, one that could eventually help discover...

2009-10-08 00:00:00

NANTONG CITY, China, Oct. 8 /PRNewswire-Asia-FirstCall/ -- Sinobiopharma, Inc. (OTC Bulletin Board: SNBP) ("Sinobiopharma") (the "Company") is pleased to announce that the Company received a certificate for the use of Gabexate mesylate as a pharmaceutical raw material (Certificate #2009S01805) from the Chinese State Food and Drug Administration ("SFDA"). Gabexate Mesylate is a serine proteinase inhibitor used therapeutically in the treatment of pancreatitis, disseminated...

2009-06-29 09:55:27

Important modulator of immune cell entry into the brain -- perhaps new target for the therapyIt has been known for a long time that T cells can attack the body's own structures and, if they infiltrate the CNS, cause diseases such as multiple sclerosis (MS). The T cells damage the myelin sheath, the material that surrounds and protects the fibers of nerve cells. This damage slows down or blocks messages between the brain and the body, leading to various symptoms of MS such as impaired...